Followers | 48 |
Posts | 3355 |
Boards Moderated | 0 |
Alias Born | 02/15/2009 |
Monday, May 25, 2020 6:49:48 PM
The Moderna vaccine company that’s attempting to use the mRNA technology platform to rapidly create a coronavirus vaccine has been widely accused of a pump-and-dump stock scheme involving the pumping of company stocks with widely-touted press releases that claim positive outcomes for phase 1 vaccine trials.
But buried in Moderna’s own press release is an admission that Moderna’s mRNA-1273 vaccine caused serious injuries in 15% of patients who were injected.
Importantly, the so-called “grade 3 systemic symptoms,” which require medical intervention, appeared after the second round of vaccine injections, underscoring the suspicion that the first vaccine injection sets up the body for an injurious (or even deadly) reaction upon a second exposure to a pathogen.
High-dose subjects suffered “serious adverse events”
The injuries were reported at the 250 ug (microgram) dose levels, and Modern removed those participants from any consideration of antibody reporting, restricting their antibody claims to those who received lower doses.
250 ug is a very tiny dose, just 1/4th of 1/1000th of a gram. Many vaccines inject subjects with similar doses.
“Three of the 15 human guinea pigs in the high dose cohort (250 mcg) suffered a ‘serious adverse event’ within 43 days of receiving Moderna’s jab,” commented Children’s Health Defense:
Moderna did not release its clinical trial study or raw data, but its press release, which was freighted with inconsistencies, acknowledged that three volunteers developed Grade 3 systemic events defined by the FDA as “Preventing daily activity and requiring medical intervention.”
… A vaccine with those reaction rates could cause grave injuries in 1.5 billion humans if administered to “every person on earth”.
Moderna skipped animal trials and years of human trials in mad rush to market
Moderna says in its press release that it’s rushing to a phase 3 trial in early July, skipping the normal 1-3 years that it would usually take to determine vaccine safety in phase 1 and phase 2 trials. The fact that the Moderna vaccine caused a 15% rate of serious adverse events during the phase 1 trial hasn’t stopped the vaccine company from exposing others to its risky, experimental vaccine. If anything, the company is doubling down on testing it in more people, albeit at lower doses that it hopes won’t produce the same level of potentially injurious side effects.
These outcomes are particularly disappointing because the most hazardous hurdle for the inoculation is still ahead: challenging participants with wild COVID infection. Past attempts at developing COVID vaccines have always faltered at this stage as both humans and animals achieved robust antibody response then sickened and died when exposed to the wild virus.
In other words, even if the mRNA vaccine produces antibodies, that’s nowhere close to achieving a “safe” vaccine. In previous vaccine trials involving animal subjects treated with SARS-CoV-1 pathogens, the animal subjects died when exposed to subsequent infections because the vaccine set up their bodies for a deadly cytokine storm — an “enhanced” immune reaction that leads to systemic inflammation and death.
CHD characterizes the Moderna vaccine trial results as a “catastrophe,” and the CEO of Moderna, Stephane Bancel, previously admitted that mRNA injections into the body actually cause flu-like immune responses that are undesirable:
Is it any wonder why Moderna executives are selling their own stock shares like mad, even as they claim to be ramping up a world-changing breakthrough that, if true, would earn stockholders a windfall of profits?
What do Moderna executives know, in other words, that they aren’t telling us?
The most likely answer is that the Moderna vaccine is highly unlikely to ever work without imparting enormous safety risks to patients.
Recent MRNA News
- Delta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More News • IH Market News • 04/10/2024 11:13:48 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/11/2024 08:08:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 01:05:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 08:22:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/06/2024 08:13:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:56:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 10:52:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 08:32:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 08:25:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:33:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:25:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 10:28:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:49:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:39:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:37:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:32:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:24:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/29/2024 09:15:37 PM
- U.S. Stocks May Lack Direction Following Yesterday’s Modest Pullback • IH Market News • 02/27/2024 02:14:46 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/23/2024 09:21:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 09:04:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/22/2024 08:39:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 11:32:03 AM
- U.S. Futures Surge on Nvidia’s Stellar Performance, Global Markets Respond Positively • IH Market News • 02/22/2024 11:05:39 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/16/2024 09:20:21 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM